Description
The search for novel risk factors for Alzheimer disease relies on access to accurate and deeply phenotyped datasets. The Memory and Aging Project at the Knight-ADRC (Knight ADRC-MAP) collects plasma, CSF, fibroblast, neuroimaging clinical and cognition data longitudinally and autopsied brain samples. We are using multi-tissue (brain, CSF and plasma) multi-omic data (genetics, epigenomics, transcriptomics, proteomics and metabolomics) to identify novel risk and protective variants, create new prediction models and identify drug targets. The study cohort includes MAP participants from the Knight-ADRC at Washington University in St. Louis (MO). MAP participants have to be at least 65 years old and have no memory problems or mild dementia at the time of enrollment. There is no age at onset criteria for this cohort. Cases had to have a CDR >=0.5 whereas controls had to have a CDR=0 at last assessment. AD definition is based on a combination of both clinical and pathological information if available. Pathologic diagnosis will overrule clinical diagnosis. Participants are Non-Hispanic white from North America (95%) and African American (5%). Autopsy information was provided if available, but it is not a requirement for enrollment.
Additional information about Knight ADRC datasets available through NIAGADS can be found on the Knight ADRC Collection page.
PI
Carlos Cruchaga, Ph.D.
Washington University in St. Louis
Maria Victoria Fernandez, Ph.D.
Washington University in St. Louis
Oscar Harari, Ph.D.
Washington University in St. Louis
Related Datasets
- Alzheimer’s disease (AD) is the most prevalent cause of dementia. While there is no effective treatment for AD, a growing body of evidence points to passive immunotherapy with monoclonal antibodies…
- The identification of genetic risk factors for Alzheimer’s Disease (AD) provides additional to support that multiple pathways contribute to its onset and progression. However, the metabolomic and lipidomic profiles altered…
- Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder with many biological processes, and molecular changes. The etiology of AD is complex and not specific to a single genetic factor. Epigenetic…
- The search for novel risk factors for Alzheimer disease relies on access to accurate and deeply phenotyped datasets. The Memory and Aging Project at the Knight-ADRC (Knight ADRC-MAP) collects plasma,…
- Understanding the tissue-specific genetic controls of protein levels is essential to uncover mechanisms of post-transcriptional gene regulation. We previously generated a genomic atlas of protein levels in three tissues relevant…
- This dataset includes sequencing data and harmonized phenotypes from cohorts sequenced by the Alzheimer’s Disease Sequencing Project and other AD and Related Dementia’s studies. Samples are processed using a common…
- This dataset contains summary statistics of a genome-wide association study for established biomarkers (Cerebrospinal fluid (CSF) tau, tau phosphorylated at threonine 181 (ptau), and Aβ₄₂) for Alzheimer’s disease. The GWAS…
- This dataset is part of a genome-wide association study investigating the role of Clusterin (CLU – Endophenotype for AD) in Alzheimer’s Disease. It includes imputed genotype data with 6,015,512 SNPs,…
- This dataset contains summary statistics of a genome-wide association study to understand the role of Clusterin (CLU – Endophenotype for AD) in Alzheimer’s Disease. The GWAS data for these summary…
- Cerebrospinal fluid (CSF) tau, tau phosphorylated at threonine 181 (ptau), and Aβ₄₂ are established biomarkers for Alzheimer’s disease (AD) and have been used as quantitative traits for genetic analyses. This…
Related Sample Sets
- KnightADRC samples were sequenced at MGI on the HiSeq4000 machine. 75 samples were sequenced using the IDT xGen Exome Whole Exome Research Panel v1.0 w/Custom Spike-In Baits and 586 samples…
- Knight ADRC samples were whole-genome sequenced at Broad/Genentech either on the HiSeqX or HiSeq2000/2500 machine. Samples in either format (BAM files from hg37 build and FASTQ files) were sent to…
- The microglia profile of the Parietal lobe of 44 donors from the Knight ADRC were sequenced using 10X genomics 3’ Chemistry v3 (10,000 nuclei per donor, 50,000 reads per nuclei),…
- The identification of genetic risk factors for Alzheimer’s Disease (AD) provides additional to support that multiple pathways contribute to its onset and progression. However, the metabolomic and lipidomic profiles altered…
- Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with many biological processes, and molecular changes. The etiology of AD is complex and not specific to a single genetic factor. Epigenetic…
- The data being submitted is from participants from the Knight-ADRC MAP study. Genotyping for 4495 participants were generated through 10 different genotyping arrays (Infinium CoreExome-24, Infinium Neuro Consortium Array, Infinium…
- Understanding the tissue-specific genetic controls of protein levels is essential to uncover mechanisms of post-transcriptional gene regulation. We previously generated a genomic atlas of protein levels in three tissues relevant…
- Cerebrospinal fluid (CSF) tau, tau phosphorylated at threonine 181 (ptau), and Aβ₄₂ are established biomarkers for Alzheimer's disease (AD) and have been used as quantitative traits for genetic analyses. This…
- This dataset is part of a genome-wide association study investigating the role of Clusterin (CLU - Endophenotype for AD) in Alzheimer's Disease. It includes imputed genotype data with 6,015,512 SNPs,…
Cohorts
- The search for novel risk factors for Alzheimer disease relies on access to accurate and deeply phenotyped datasets. The Memory and Aging Project at the Knight-ADRC (Knight ADRC-MAP) collects plasma,…
- The FBS collection is a longitudinal, multi-center late onset AD sibling genetics initiative. This NIA-funded study began in 2,002 and maintains DNA and cell lines on families with 2 or…
- The NIA ADRC cohort included subjects ascertained and evaluated by the clinical and neuropathology cores of the 32 NIA-funded ADRCs. Data collection is coordinated by the National Alzheimer’s Coordinating Center…
- 131 families with LOAD (751 individuals) were ascertained and evaluated through the University of Washington Alzheimer Disease Research Center. Clinical and neuropathological assessments of cases and controls, including blood sampling,…
Grants
National Institutes of Health (R01-AG044546, P01-AG003991, RF1-AG053303, NIH P50-AG05681, P01-AG026276, U24-AG21886, U24-AG026395 and U01-AG058922).
The Alzheimer Association (NIRG-11-200110, BAND-14-338165 and BFG-15-362540).
Acknowledgement
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
For investigators using Charles F. and Joanne Knight Alzheimer’s Disease Research Center data:
This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
See below for additional dataset specific acknowledgments:
For use of the ADSP-PHC harmonized phenotypes deposited within dataset, ng00067, use the following statement:
The Memory and Aging Project at the Knight-ADRC (Knight-ADRC), supported by NIH grants R01AG064614, R01AG044546, RF1AG053303, RF1AG058501, U01AG058922 and R01AG064877 to Carlos Cruchaga. The recruitment and clinical characterization of research participants at Washington University was supported by NIH grants P30AG066444, P01AG03991, and P01AG026276. Data collection and sharing for this project was supported by NIH grants RF1AG054080, P30AG066462, R01AG064614 and U01AG052410. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
For use of ng00050 and ng00052, use the following statement:
This work was supported by Pfizer and grants from the National Institutes of Health (R01-AG044546, P01-AG003991), and the Alzheimer's Association (NIRG-11–200110). This research was conducted while Carlos Cruchaga was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. Carlos Cruchaga is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The recruitment and clinical characterization of research participants at Washington University were supported by NIHP50 AG05681, P01 AG03991, and P01 AG026276. Some of the samples used in this study were genotyped by the ADGC and GERAD. ADGC is supported by grants from the NIH (#U01AG032984) and GERAD from the Wellcome Trust (GR082604MA) and the Medical Research Council (G0300429). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace; Merck; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Related Publications
Fernández MV, Budde J, Del-Aguila JL, IbañezL, Deming Y, Harari O, Norton J, Morris JC, Goate AM; NIA-LOAD family study group; NCRAD, Cruchaga C. Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. Front Neuroscience 2018; 12:209. PMCID: PMC5893779
Fernández MV, Kim JH, Budde JP, Black K, Medvedeva A, Saef B, Deming Y, Del-Aguila J, IbañezL, Dube U, Harari O, Norton J, Chasse R, Morris JC, Goate A; NIA-LOAD family study group; NCRAD, Cruchaga C. Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS 2017;13(11):e1007045. doi: 0.1371/journal.pgen.1007045. PMCID: PMC5683650
Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM; Dominantly Inherited Alzheimer Network (DIAN); Disease Neuroimaging Initiative (ADNI); NIA-LOAD family study, Harari O. Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. AlzheimersDement 2018; (2):205-214. PMCID:PMC5803427
Ridge PG, Karch CM, Hsu S, Arano I, TeerlinkCC, Ebbert MTW, Gonzalez Murcia JD, Farnham JM, Damato AR, Allen M, Wang X, Harari O, Fernandez VM, Guerreiro R, Bras J, Hardy J, Munger R, Norton M, Sassi C, Singleton A, Younkin SG, Dickson DW, Golde TE, Price ND, Ertekin-Taner N, Cruchaga C, Goate AM, Corcoran C, Tschanz J, Cannon-Albright LA, Kauwe JSK; Alzheimer’s Disease Neuroimaging Initative. Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience. Genome Med. 2017; 9(1):100. PMCID: PMC5706401
Fernández MV, Black K, Carrell D, SaefB, Budde J, Deming Y, Howells B, Del-Aguila JL, Ma S, Bi C, Norton J, Chasse R, Morris J, Goate A, Cruchaga C; NIA-LOAD family study group, NCRAD. SORL1 variants across Alzheimer’s disease European American cohorts. Eur J Hum Genet 2016; 24(12):1828-1830. PMCID: PMC5117924
Fernández MV, Black K, Carrell D, SaefB, Budde J, Deming Y, Howells B, Del-Aguila JL, Ma S, Bi C, Norton J, Chasse R, Morris J, Goate A, Cruchaga C; NIA-LOAD family study group, NCRAD. SORL1 variants across Alzheimer’s disease European American cohorts. Eur J Hum Genet 2016; 24(12):1828-1830. PMCID: PMC5117924